Description: Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. This revolutionary strategy stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy. We have applied DECS to a wide range of clinical therapies, including the de
medicine (3131) drug (627) patients (493) switching (87) deuterium (20) chiral (7)